These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26743448)

  • 1. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
    J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
    Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
    Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
    Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 10. Apremilast and its role in psoriatic arthritis.
    Sandhu VK; Eder L; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.
    Strand V; Elaine Husni M; Betts KA; Song Y; Singh R; Griffith J; Beppu M; Zhao J; Ganguli A
    BMC Rheumatol; 2018; 2():3. PubMed ID: 30886954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.
    Sideris E; Corbett M; Palmer S; Woolacott N; Bojke L
    Pharmacoeconomics; 2016 Nov; 34(11):1101-1110. PubMed ID: 27272887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Song GG; Lee YH
    Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.